Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity

Current Opinion in Investigational Drugs

Volumn 10, Issue 10, 2009, Pages 1117-1125

  Padwal, R ^a  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIOBESITY AGENT; BUPROPION PLUS NALTREZONE; CONTRAVE; NALTREXONE; PLACEBO; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMORBIDITY; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; INGUINAL HERNIA; INSOMNIA; MENTAL DISEASE; NAUSEA; OBESITY; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS MENINGITIS; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; APPETITE; BUPROPION; CONTROLLED CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DOPAMINE UPTAKE INHIBITORS; DRUG COMBINATIONS; ENERGY METABOLISM; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; OBESITY; WEIGHT LOSS;

EID: 70349757017     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. 262904 Pondimin and Redux to be voluntarily withdrawn/action is based on new information/company says it is taking the most prudent course of action for patients and doctors. Wyeth-Ayerst Laboratories PRESS RELEASE 1997 September 15
2. 669262 Orexigen Therapeutics appoints Graham Cooper as Chief Financial Officer Orexigen Therapeutics Inc PRESS RELEASE 2006 May 24
3. 669584 Orexigen Therapeutics Inc: Products Orexigen Therapeutics Inc COMPANY INTERNET SITE 2006 May 25
4. 673154 Bupropion and naltrexone for the treatment of obesity. Greenway FL, Anderson JW, Atkinson RL, Fujioka K, Gadde KM, Gupta AK, Neil PMO, Schumacher D, Smith DK, Whitehouse MJ, Cruickshank S et al DIABETES 2006 55 6 Suppl 1 Abs 1706 P
5. 764216 Drug treatments for obesity: Orlistat, sibutramine, and rimonabant. Padwal RS, Majumdar SR LANCET 2007 369 9555 71-77
6. 804452 FDA advisory committee did not recommend approval of rimonabant (ZIMULTI) for use in obese and overweight patients with associated risks factors. Sanofi-Aventis PRESS RELEASE 2007 June 13
7. 833174 Orexigen announces positive clinical results of its proprietary naltrexone sustained release formulation for use in Contrave. Orexigen Therapeutics Inc PRESS RELEASE 2007 September 25
8. 855652 Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Christensen R, Kristensen PK, Bartels EM, Blidda H, Astrup A LANCET 2007 370 9600 1706-1713
9. 860142 Orexigen Therapeutics initiates fourth phase III trial for Contrave to treat obesity. Orexigen Therapeutics Inc PRESS RELEASE 2007 December 11
10. 865181 Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. Rucker D, Padwal R, Li SK, Curioni C, Lau DCW BR MED J 2007 335 7631 1194-1199
11. 865890 Cardiovascular responses to weight management and sibutramine in high-risk subjects: An analysis from the SCOUT trial. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Sharma A, Brisco W, Deaton R, Shepherd G, James P EUR HEART J 2007 28 23 2915-2923
12. 866900 Obesity. Haslam DW, James WP LANCET 2005 366 9492 1197-1209
13. 867365 Long-term persistence with orlistat and sibutramine in a population-based cohort. Padwal R, Kezouh A, Levine M, Etminan M INT J OBESITY 2007 31 10 1567-1570
14. 867374 Pharmacotherapy for obesity. Ioannides-Demos LL, Proietto J, McNeil JJ DRUGS 2005 65 10 1391-1418
15. 867375 Phenylpropanolamine and the risk of hemorrhagic stroke. Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, Morgenstern LB, Wilterdink JL, Horwitz RI N ENGL J MED 2000 343 25 1826-1832
16. 867643 The surgeon general's call to action to prevent and decrease overweight and obesity. US DEPARTMENT HEALTH HUM SERVICES, PUBLIC HEALTH SERVICE, OFFICE SURGEON GENERAL 2001 US GPO, Washington, USA 1-60
17. 867668 Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - The evidence report. National Institutes of Health. OBES RES 1998 6 Suppl 2 51S-209S
18. 875015 Obesity: New products on the horizon. IMS Health INTERNET SITE 2009 August 04
19. 903408 Orexigen Therapeutics announces completion of patient enrollment in phase III clinical program for Contrave. Orexigen Therapeutics Inc PRESS RELEASE 2008 May 07
20. 923784 Orexigen initiates second phase IIb Empatic trial on schedule. Orexigen Therapeutics Inc PRESS RELEASE 2008 July 09
21. 949063 Orexigen Therapeutics presents data on its proprietary formulation of naltrexone sustained release (SR) used in Contrave. Orexigen Therapeutics Inc PRESS RELEASE 2008 October 06
22. 955619 The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. European Agency for the Evaluation of Medicinal Products PRESS RELEASE 2008 October 23
23. 955641 sanofi-aventis is complying with the EMEA's recommendation to temporarily suspend the marketing authorisation of Acomplia in obese and overweight patients. Sanofi-Aventis PRESS RELEASE 2008 October 23
24. 967134 Double-blind, placebo-, bupropion- and naltrexonecontrolled study of the efficacy and safety of 3 doses of naltrexone-bupropion SR combination therapy in obesity: Effects on total and visceral adipose tissue and CV risk markers. Greenway FL, Fujioka K, Gupta AK, Smith SR, Guttadauria M, Tollefson G, Erickson J, Dunayevich E, Cowley MA NAASO 2007 October 21 Abs 269-PIA
25. 967145 Bupropion and naltrexone interact synergistically to decrease food intake in mice. Sinnayah P, Wallingford N, Evans A, Cowley M NAASO 2007 October 23 Abs 567-P
26. 967154 Naltrexone and bupropion reduce the prevalence of the metabolic syndrome. Greenway FL, Erickson J, Dunayevich E, Tollefson G ANN MEET AM DIABETES ASSOC 2008 68 Abs 2735-PO
27. 967168 Weight loss with bupropion and naltrexone improves markers of insulin-resistance. Greenway FL, Smith SR, Fujioka K, Gupta AK, Robinson J, Dunayevich E, Guttadauria M, Tollefson GD, Cowley MA ANN MEET AM DIABETES ASSOC 2007 67 Abs 45LB
28. 967172 The naltrexone-bupropion combination reduces the prevalence of the metabolic syndrome and improves cardiometabolic markers in at-risk subjects. Erickson J, Greenway F, Dunayevich E, Tollefson G OBESITY 2008 16 Suppl 1 Abs 317-P
29. 967212 Rational design of a combination medication for the treatment of obesity. Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, Gadde KM, Gupta AK, O'Neil P, Schumacher D, Smith D et al OBESITY 2008 17 1 30-39 •• Details preclinical studies to establish the effect of the naltrexone and bupriopion combination in vitro and in vivo. The paper also describes a phase II clinical trial in patients with uncomplicated obesity in which the combined treatment provided sustained weight loss over the period of the trial; this weight loss was enhanced compared with the use of either drug as a monotherapy. The combination treatment was well tolerated.
30. 970385 Qnexa meets primary endpoint by demonstrating superior weight loss over components and placebo in the 28-week equate study (OB-301). VIVUS Inc PRESS RELEASE 2008 December 11
31. 972595 Takeda starts phase 3 clinical studies of ATL-962a treatment for obesity and related diseases in Japan. Takeda Pharmaceutical Co Ltd PRESS RELEASE 2008 December 22
32. 974022 Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: A preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) trial. Maggioni AP, Caterson I, Coutinho W, Finer N, Van Gaal L, Sharma AM, Torp-Pedersen C, Bacher P, Shepherd G, Sun R, James P et al J CARDIOVASC PHARMACOL 2008 52 5 393-402
33. 976407 Taisho reaches agreement on the development and sale of anti-obesity drug orlistat, in Japan. Taisho Pharmaceutical Co Ltd PRESS RELEASE 2009 January 13
34. 989194 GlaxoSmithKline plc: Annual report 2008. GlaxoSmithKline plc ANNUAL REPORT 2009 February 24
35. 996109 Arena Pharmaceuticals announces positive lorcaserin pivotal phase 3 obesity trial results: Meets all primary efficacy and safety endpoints. Arena Pharmaceuticals Inc PRESS RELEASE 2009 March 30
36. 1001553 GlaxoSmithKline launches Alli (orlistat 60 mg). GlaxoSmithKline plc PRESS RELEASE 2009 April 20
37. 1008247 Orexigen Therapeutics announces Jay Hagan as Senior Vice President, Corporate Development and Strategy Orexigen Therapeutics Inc PRESS RELEASE 2009 May 11
38. 1013401 Naltrexone + bupropion combination causes significant weight loss: A 56-week phase 3 study. Wadden T, Klein S, Greenway FL, Erickson J, Kim DD, Dunajevich E, Pi-Sunyer FX ANN MEET AM DIABETES ASSOC 2009 69 Abs 37-OR • Details the phase III clinical trial NCT00456521, which assessed Contrave in patients who were overweight or obese. The decrease in body weight observed at 56 weeks was approximately 2-fold higher in the Contrave group compared with placebo. Additionally, more patients receiving Contrave achieved a ≥ 5, 10 and 15% body-weight loss than those receiving placebo. Appetite control was also significantly improved in the Contrave group.
39. 1016291 NeuroSearch successfully completes end of phase II meeting with the FDA for tesofensine, a treatment for obesity. NeuroSearch A/S PRESS RELEASE 2009 June 08
40. 1017222 Orexigen Therapeutics announces in-licensing of key patents to further strengthen its Intellectual Property Estate for Contrave Orexigen Therapeutics Inc PRESS RELEASE 2009 June 11
41. 1019445 Naltrexone + bupropion combination causes significant weight loss without worsening psychiatric symptoms. Klein S, Wadden T, Erickson J, Dunayevich E, Billes SK, Kim DD, Pi-Sunyer FX ANN MEET AM DIABETES ASSOC 2009 69 Abs 1730-P
42. 1019446 Naltrexone + bupropion combination causes weight loss and improves quality of life. Wadden T, Pi-Sunyer FX, Erickson J, Dunayevich E, Guttadauria M, Kim DD, Klein S ANN MEET AM DIABETES ASSOC 2009 69 Abs 1731-P
43. 1019448 Combination therapy with naltrexone + bupropion causes significant weight loss and improves cardiometabolic parameters in obese individuals: A randomized phase 3 study over 56 weeks. Pi-Sunyer FX, Klein S, Greenway FL, Erickson J, Guttadauria M, Kim DD, Dunayevich E, Wadden T ANN MEET ENDOCRINE SOC 2009 91 Abs OR18-5 • Details the phase III clinical trial NCT00456521, which assessed Contrave in patients who were overweight or obese. The decrease in body weight observed at 56 weeks was approximately 2-fold higher in the Contrave group compared with the placebo group. Additionally, more patients receiving Contrave achieved ≥ 5, 10 and 15% losses in body weight than those receiving placebo. An analysis of cardiovascular risk parameters in the Contrave cohort revealed improvement in waist circumference and in HDL, triglyceride and C-reactive protein levels.
44. 1026853 Anatomy and regulation of the central melanocortin system. Cone RD NAT NEUROSCI 2005 8 5 571-578
45. 1026854 Central control of body weight and appetite. Woods SC, D'Alessio DA J CLIN ENDOCRINOL METAB 2008 93 11 S37-S50
46. 1026855 Evidence of interactions between melanocortin and opioid systems in regulation of feeding. Olszewski PK, Wirth MM, Grace MK, Levine AS, Giraudo SQ NEUROREPORT 2001 12 8 1727-1730
47. 1026878 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. Lau DCW, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E CMAJ 2007 176 8 S1-S13
48. 1026906 Pharmacological treatment of the overweight patient. Bray GA, Greenway FL PHARMACOL REV 2007 59 2 151-184
49. 1026910 Effects of long-term therapy with naltrexone on body-weight in obesity. Atkinson RL, Berke LK, Drake CR, Bibbs ML, Williams FL, Kaiser DL CLIN PHARMACOL THER 1985 38 4 419-422
50. 1028827 Obesity and overweight. Fact sheet No 311. World Health Organization INTERNET SITE 2006 September 30
51. 1029353 Syntheses of C-14 and tritium labeled forms of bupropion hydrochloride. A novel antidepressant. Hill JA, Scharver JD J LABELLED COMPD RADIOPHARM 1988 25 10 1095-1104
52. 1030962 Recreational use of aminorex and pulmonary hypertension. Gaine SP, Rubin LJ, Kmetzo JJ, Palevsky HI, Traill TA CHEST 2000 118 5 1496-1500
53. 1030982 15 years of clinical experience with bupropion HCl: From bupropion to bupropion SR to bupropion XL. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA PRIM CARE COMPANION J CLIN PSYCHIATRY 2005 7 3 106-113
54. 1030983 Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Sinclair JD ALCOHOL ALCOHOL 2001 36 1 2-10
55. 1032115 Orexigen Therapeutics announces second quarter 2009 financial results. Orexigen Therapeutics Inc PRESS RELEASE 2009 August 06
56. 1033117 Cause-specific excess deaths associated with underweight, overweight, and obesity. Flegal KM, Graubard BI, Williamson DF, Gail MH JAMA-J AM MED ASSOC 2007 298 2028-2037
57. 1033777 Methods for voluntary weight loss and control. NIH technology assessment conference panel. Consensus development conference, 30 March to 1 April 1992. No authors listed ANN INTERN MED 1993 119 7 Pt 2 764-770
58. 1034550 FDA approves Orlistat for over-the-counter use. FDA PRESS RELEASE 2007 February 07
59. 1034929 Orexigen Therapeutics Inc: Form 10-Q. Orexigen Therapeutics Inc FORM 10-Q 2009 August 03